Clin Oncol | Volume 2, Issue 1 | Mini Review | Open Access

Choline PET/CT Imaging for Management of Prostate Cancer

Kazuhiro Kitajima1*, Kazuhito Fukushima1, Koichiro Yamakado2, Shozo Hirota2 and Shingo Yamamoto3

1Department of Radiology, Division of Nuclear Medicine and PET Center, Hyogo College of Medicine, Japan
2Department of Radiology, Hyogo College of Medicine, Japan
3Department of Urology, Hyogo College of Medicine, Japan

*Correspondance to: Kazuhiro Kitajima 

Fulltext PDF

Abstract

Whole-body Positron Emission Tomography/Computed Tomography (PET/CT) with [11C]- and [18F]-labeled choline derivatives has emerged as a promising molecular imaging modality for evaluation of prostate cancer. 11C-choline and 18F-flurocholine PET/CT examinations have been shown to be effective for restaging of prostate cancer patients with biochemical disease recurrence after undergoing definitive therapy, especially those with a serum prostate-specific antigen level >1.0 ng/mL. On the other hand, they have more limited roles for initial staging of prostate cancer or detection of tiny lymph node metastasis, due to the low spatial resolution inherent with PET. Overall, these modalities are most useful for cases with a high pre-test suspicion of metastatic disease. Here, we review the current clinical roles of 11C-choline and 18F-fluorocholine PET/CT for management of patients with prostate cancer.

Keywords:

prostate cancer; Staging; Restaging; 11C-choline; 18F-fluorocholine; Positron emission tomography/computed tomography (PET/CT)

Citation:

Kitajima K, Fukushima K, Yamakado K, Hirota S, Yamamoto S. Choline PET/CT Imaging for Management of Prostate Cancer. Clin Oncol. 2017; 2: 1218.

Subscribe to Our Newsletter